MMP2 and pancreatic neoplasm: We provide evidence that BITC dose-dependently inhibits the migration, invasion, and neovascularization of human pancreatic cancer and endothelial cells by targeting HIF1α, VEGF, MMP-2, and Rho-GTPases through the STAT-3 dependent pathway.